SEK 5.19
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm,...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of ONCO.ST is 5.5 and suggests 6% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
